Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics
about
Therapeutic Strategies in HCC: Radiation ModalitiesA review of the infection-associated cancers in North African countriesDevelopment and novel therapeutics in hepatocellular carcinoma: a reviewThe Role of Diffusion-Weighted Imaging (DWI) in Locoregional Therapy Outcome Prediction and Response Assessment for Hepatocellular Carcinoma (HCC): The New Era of Functional Imaging BiomarkersEag1 channels as potential early-stage biomarkers of hepatocellular carcinomaEfficacy of Nucleot(s)ide Analogs Therapy in Patients with Unresectable HBV-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway.Autoantibodies against glucose-regulated protein 78 as serological biomarkers in metastatic and recurrent hepatocellular carcinomaExtending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.INHIBITORY EFFECT OF CHITOSAN OLIGOSACCHARIDE ON HUMAN HEPATOMA CELLS IN VITRO.Combined aberrant expression of N-Myc downstream-regulated gene 2 and CD24 is associated with disease-free survival and overall survival in patients with hepatocellular carcinoma.Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cellsHepatocellular carcinoma: Surgeon's view on latest findings and future perspectives.Evaluation of 11C-acetate and 18F-FDG PET/CT in mouse multidrug resistance gene-2 deficient mouse model of hepatocellular carcinoma.Synergistic Induction of Potential Warburg Effect in Zebrafish Hepatocellular Carcinoma by Co-Transgenic Expression of Myc and xmrk OncogenesMicroRNA-3127 promotes cell proliferation and tumorigenicity in hepatocellular carcinoma by disrupting of PI3K/AKT negative regulationUpregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway.Microvascular invasion in hepatocellular carcinoma overexpression promotes cell proliferation and inhibits cell apoptosis of hepatocellular carcinoma via inhibiting miR-199a expressionAn Encapsulation of Gene Signatures for Hepatocellular Carcinoma, MicroRNA-132 Predicted Target Genes and the Corresponding OverlapsFrom big data to diagnosis and prognosis: gene expression signatures in liver hepatocellular carcinoma.MicroRNA-519a promotes proliferation and inhibits apoptosis of hepatocellular carcinoma cells by targeting FOXF2.Prevalence of K-Ras mutations in hepatocellular carcinoma: A Turkish Oncology Group pilot study.Serum Metabolomics to Identify the Liver Disease-Specific Biomarkers for the Progression of Hepatitis to Hepatocellular Carcinoma.SR4 Uncouples Mitochondrial Oxidative Phosphorylation, Modulates AMP-dependent Kinase (AMPK)-Mammalian Target of Rapamycin (mTOR) Signaling, and Inhibits Proliferation of HepG2 Hepatocarcinoma Cells.Cancer stem cells in hepatocellular carcinoma--an immunohistochemical study with histopathological association.Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE StudyNa+/K+-ATPase α1 subunit, a novel therapeutic target for hepatocellular carcinomaClinical outcome of immunotherapy with dendritic cell vaccine and cytokine-induced killer cell therapy in hepatobiliary and pancreatic cancer.microRNA-497 inhibits cell proliferation and induces apoptosis by targeting YAP1 in human hepatocellular carcinoma.Protein phosphatase 2A-B55δ enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b.Comprehensive Circular RNA Profiling Reveals That hsa_circ_0005075, a New Circular RNA Biomarker, Is Involved in Hepatocellular Crcinoma Development.National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma.MicroRNA-155-3p promotes hepatocellular carcinoma formation by suppressing FBXW7 expression.Expression and diagnostic value of CCT3 and IQGAP3 in hepatocellular carcinoma.Clinical Presentation, Risk Factors, and Treatment Modalities of Hepatocellular Carcinoma: A Single Tertiary Care Center ExperienceHigh leukocyte mtDNA content contributes to poor prognosis through ROS-mediated immunosuppression in hepatocellular carcinoma patientsBCAT1 promotes tumor cell migration and invasion in hepatocellular carcinoma.Lrig1 is a positive prognostic marker in hepatocellular carcinoma.Plasma metabolomic analysis of human hepatocellular carcinoma: Diagnostic and therapeutic studyIGF-II induced by hepatitis B virus X protein regulates EMT via SUMO mediated loss of E-cadherin in mice.
P2860
Q26738658-1D1DEE38-AC9E-421E-9043-CE2F1335EA73Q26741909-8013C8D9-78F4-44EC-9159-F4C7CDDD146FQ26752854-44337CB8-90E0-4B92-9022-59C2B1D6650CQ26768460-94379FEC-91DA-4E1D-8B70-594FECB28309Q28069313-5BFD9946-2248-4452-BEAB-C64F2FA977FDQ30234870-8AB22A2A-EF62-400E-BF74-69B374BC52BBQ33607585-7E5203F2-89C2-4FE9-841B-FA0A6EE9BA76Q33648667-479D0CB2-70B2-4C36-A175-754898FA06C4Q33648955-2982A17F-9905-401E-839D-D544D09BC804Q33800404-33699E0A-CFCA-4110-A9FC-01DE575050ADQ34416873-54DF9D00-383C-4A98-91C1-88E43D9BC27DQ35176419-0C7B61A9-9761-45C0-9CC4-0E1D46C48707Q35626761-5FB35296-9B55-41DE-8FAE-8F1B309F858BQ35633633-9F276ABB-0FA2-4F31-8A49-00987067934EQ35683220-E2B26262-81EA-4A05-84F6-CE4AD350CBE6Q35742539-0A7EE1EC-CDEB-4362-BF40-EB60CB671085Q35781460-7039F54C-FA8E-42BF-A771-E6369CEBB2E6Q36015140-2919545C-B2B4-4184-BB1E-00E1DB29BF9DQ36088484-97AD6B95-BFA9-4D00-B285-5AD48364A7C7Q36313998-4CF2B5E3-43D5-4189-9776-7CFC6BF2BFCCQ36320426-A9B78C4A-16DD-4894-BDD4-6373555AA4CEQ36335286-3B1A12DC-E292-4F74-ADEF-34C9DECF41EAQ36360941-A09F31F8-B981-44EB-A8FC-19CD4A365CE1Q36381908-E1F4A26A-EDFA-4FF0-8BA2-D6F2886F47E2Q36383646-AD8789D3-5464-4274-A1CE-0490775E5C9FQ36404761-32C50C14-D065-4D5A-81B9-F178F3678574Q36414017-12E45C00-25FA-48D2-91C2-703EDD7D14EDQ36502870-E9DF61D1-085C-4EE4-838B-7FC80FFA0C48Q36766747-DD104786-CB62-41B0-AACC-9BBD534E1F24Q36796805-FEB0B715-90AF-443D-940D-E78CEB4D4E7CQ36988797-B2C704E9-FB35-4C53-9E96-66A832E13A97Q37000692-11F6C2C2-DBCC-420F-B3E2-664D4EFEE7CDQ37010976-ED368F39-4CCF-4350-BC88-B5BA4658E459Q37073766-4ADEF7C2-7C2F-415F-BD4E-1A403C10B4F4Q37157007-345A59FD-B050-4475-845B-944D9B920DAFQ37225687-D1C837CD-EAB6-43D5-872A-EA576392D0F9Q37288407-24A7BCC4-4AD2-45E1-84FB-9EF6B85ABCE2Q37426842-FBBC3E67-9FBC-4B90-9551-A53BA719C6C7Q37565131-6C6D3611-5212-4D97-A143-B19CE3E48BF4Q37636729-F0690CAE-7A65-4F27-A569-D90B1F437C94
P2860
Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 May 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hepatocellular carcinoma: curr ...... s, diagnosis, and therapeutics
@en
Hepatocellular carcinoma: curr ...... , diagnosis, and therapeutics.
@nl
type
label
Hepatocellular carcinoma: curr ...... s, diagnosis, and therapeutics
@en
Hepatocellular carcinoma: curr ...... , diagnosis, and therapeutics.
@nl
prefLabel
Hepatocellular carcinoma: curr ...... s, diagnosis, and therapeutics
@en
Hepatocellular carcinoma: curr ...... , diagnosis, and therapeutics.
@nl
P2093
P2860
P356
P1476
Hepatocellular carcinoma: curr ...... s, diagnosis, and therapeutics
@en
P2093
Alpna Limaye
Renumathy Dhanasekaran
Roniel Cabrera
P2860
P356
10.2147/HMER.S16316
P577
2012-05-08T00:00:00Z